美国西奈山伊坎医学院Ivan Marazzi，Yesai Fstkchyan，Laura Campisi和美国加州大学欧文分校Albert R. La Spada共同合作，近期取得重要工作进展，他们研究发现克隆扩增的CD8T细胞是肌萎缩性侧索硬化-4（ALS4）的特征。相关论文2022年6月22日在线发表于《自然》杂志上。
Title: Clonally expanded CD8 T cells characterize amyotrophic lateral sclerosis-4
Author: Campisi, Laura, Chizari, Shahab, Ho, Jessica S. Y., Gromova, Anastasia, Arnold, Frederic, Mosca, Lorena, Mei, Xueyan, Fstkchyan, Yesai, Torre, Denis, Beharry, Cindy, Garcia-Forn, Marta, Jimnez-Alczar, Miguel, Korobeynikov, Vladislav A., Prazich, Jack, Fayad, Zahi A., Seldin, Marcus M., De Rubeis, Silvia, Bennett, Craig L., Ostrow, Lyle W., Lunetta, Christian, Squatrito, Massimo, Byun, Minji, Shneider, Neil A., Jiang, Ning, La Spada, Albert R., Marazzi, Ivan
Issue&Volume: 2022-06-22
Abstract: Amyotrophic lateral sclerosis (ALS) is a heterogenous neurodegenerative disorder that affects motor neurons and voluntary muscle control1. ALS heterogeneity includes the age of manifestation, the rate of progression and the anatomical sites of symptom onset. Disease-causing mutations in specific genes have been identified and define different subtypes of ALS1. Although several ALS-associated genes have been shown to affect immune functions2, whether specific immune features account for ALS heterogeneity is poorly understood. Amyotrophic lateral sclerosis-4 (ALS4) is characterized by juvenile onset and slow progression3. Patients with ALS4 show motor difficulties by the time that they are in their thirties, and most of them require devices to assist with walking by their fifties. ALS4 is caused by mutations in the senataxin gene (SETX). Here, using Setx knock-in mice that carry the ALS4-causative L389S mutation, we describe an immunological signature that consists of clonally expanded, terminally differentiated effector memory (TEMRA) CD8T cells in the central nervous system and the blood of knock-in mice. Increased frequencies of antigen-specific CD8T cells in knock-in mice mirror the progression of motor neuron disease and correlate with anti-glioma immunity. Furthermore, bone marrow transplantation experiments indicate that the immune system has a key role in ALS4 neurodegeneration. In patients with ALS4, clonally expanded TEMRA CD8T cells circulate in the peripheral blood. Our results provide evidence of an antigen-specific CD8T cell response in ALS4, which could be used to unravel disease mechanisms and as a potential biomarker of disease state.
作者: admin 时间: 2023-9-2 21:22
渐冻症患者治疗
渐冻症患者佳音
根据微生物学、病理学、神经科学、药理学、内科学等专著和论文，肌萎缩性侧索硬化症(ALS，渐冻症)的第一位的治疗要项是抑制过度兴奋，可用伽马氨基丁酸类镇静助眠药物（便宜）、或抗谷氨酸药利鲁唑（较贵），第二位的治疗要项是抑制神经炎症反应，可用消炎解痛药、或激素类药，第三位的治疗要项是睡眠疗法，第四为其他、对症治疗等，均可口服药等简便方法治疗，可即时停止病情发展，并病情回复、回好约10-20%，救回大多数渐冻症患者宝贵生命。（2023.9.2晚10点写于东京）
(Translated by Baidu: )
According to monographs and papers in microbiology, pathology, neuroscience, pharmacology, internal medicine, and other fields, the first treatment requirement for amyotrophic lateral sclerosis (ALS) is to suppress overexcitation, which can be treated with gamma aminobutyric acid sedative and hypnotic drugs (cheap) or anti glutamic acid drug riluzole (more expensive). The second treatment requirement is to suppress neuroinflammatory reactions, which can be treated with anti-inflammatory and pain relieving drugs or hormone drugs, The third most important treatment option is sleep therapy, while the fourth is other, symptomatic treatment, which can be treated with simple methods such as oral medication. It can immediately stop the progression of the condition, and the condition can recover and improve by about 10-20%, saving the precious lives of most patients with Alzheimer's disease. (Written in Tokyo at 10pm on March 2, 2023)
（百度翻訳： ）
微生物学、病理学、神経科学、薬理学、内科学などの専門書と論文によると、筋萎縮性側索硬化症（ALS、漸凍症）の第1位の治療要項は過度の興奮を抑制することであり、ガンマアミノ酪酸系鎮静助眠薬（安価）、または抗グルタミン酸薬リノゾール（高価）、第2位の治療要項は神経炎症反応を抑制し、消炎解痛薬、ホルモン系薬、3位の治療要項は睡眠療法で、4位はその他、対症治療などで、いずれも薬を飲むなどの簡便な方法で治療し、直ちに病状の発展を停止することができ、そして病状の回復、回復は約10-20%で、多くの漸凍症患者の貴重な生命を救うことができる。（2023.9.2午後10時東京）
